2-[4-(benzyloxy)phenyl]-1,3-propanediol | 155062-29-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-[4-(benzyloxy)phenyl]-1,3-propanediol
• 英文别名: 2-[4-(benzyloxy)pheny]propane-1,3-diol；2-(4-benzyloxyphenyl)propane-1,3-diol；2-(4-(benzyloxy)phenyl)propane-1,3-diol；2-(4-phenylmethoxyphenyl)propane-1,3-diol
• CAS: 155062-29-6
• 化学式: C₁₆H₁₈O₃
• 分子量: 258.317
• InChiKey: ZBZPRBDFDOSTDK-UHFFFAOYSA-N

物化性质

• 熔点：
  124-125 °C
• 沸点：
  455.4±40.0 °C(Predicted)
• 密度：
  1.178±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-[4-(benzyloxy)phenyl]-1,3-propanediol 在 palladium on activated charcoal 吡啶 、 4-二甲氨基吡啶 、 氢气 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 32.5h， 生成
  参考文献：
  名称：

  2-Benzyl and 2-phenyl-3-hydroxypropyl pivalates as protein kinase C ligands

  摘要：

  A series of 2-benzyl and 2-phenyl-3-hydroxypropyl pivalates designed to incorporate the principal pharmacophores of phorbol esters have been synthesized and tested as PKC-alpha ligands. Among the analogues, 13c exhibited the most potent binding affinity with a K-i = 0.7 mu M. The synthesized analogues were subjected to molecular modeling analysis based on two alternative models of the phorbol pharmacophore and a docking study or 13c was carried out. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.10.051
• 作为产物：
  描述：

  4-苄氧基苯乙酸 在 lithium aluminium tetrahydride 、 硫酸 、 sodium hydride 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 反应 52.5h， 生成 2-[4-(benzyloxy)phenyl]-1,3-propanediol
  参考文献：
  名称：

  Beyond the affinity for protein kinase C: exploring 2-phenyl-3-hydroxypropyl pivalate analogues as C1 domain-targeting ligands

  摘要：

  在过去的十五年中，我们报道了针对蛋白激酶C（PKC）的C1结构域的不同系列化合物的设计和合成，这些化合物基于各种模板。

  DOI：

  10.1039/c4md00564c

文献信息

• [EN] NOVEL ANTIDIABETIC COMPOUNDS<br/>[FR] NOUVEAUX COMPOSES ANTIDIABETIQUES
  申请人：CADILA HEALTHCARE LTD

  公开号：WO2006018855A1

  公开（公告）日：2006-02-23

  Disclosed are novel compounds of general formula (I) where the symbols are as defined in the specification, their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation. The compounds are useful in the treatment of diabetes and related diseases.

  本发明涉及一类新颖的化合物，其一般式为（I），其中符号的定义如规范中所述，包括它们的互变异构体、立体异构体、药学上可接受的盐、含有它们的药物组合物、其制备方法、在医学中使用这些化合物以及其制备中涉及的中间体。这些化合物在糖尿病和相关疾病的治疗中具有用途。
• Design and synthesis of novel oxazole containing 1,3-Dioxane-2-carboxylic acid derivatives as PPAR α/γ dual agonists
  作者：Harikishore Pingali、Mukul Jain、Shailesh Shah、Pankaj Makadia、Pandurang Zaware、Ashish Goel、Megha Patel、Suresh Giri、Harilal Patel、Pankaj Patel

  DOI：10.1016/j.bmc.2008.06.050

  日期：2008.8

  A few novel 1,3-dioxane carboxylic acid derivatives were designed and synthesized to aid in the characterization of PPAR alpha/gamma dual agonists. Structural requirements for PPARalpha/gamma dual agonism of 1,3-dioxane carboxylic acid derivatives included the structural similarity with potent glitazones in fibric acid chemotype. The compounds with this pharmacophore and substituted oxazole as a lipophilic

  设计和合成了一些新颖的1,3-二恶烷羧酸衍生物，以帮助表征PPARα/γ双激动剂。1,3-二恶烷羧酸衍生物的PPARalpha /γ双激动性的结构要求包括与强酸格列酮在纤维酸化学型中的结构相似性。合成了具有该药效团和取代的恶唑作为亲脂性杂环尾巴的化合物，并在动物模型中评估了其体外PPAR激动剂的潜力以及体内降血糖和降血脂的功效。铅化合物2-甲基-c-5- [4-（5-（甲基-2-（4-甲基苯基）-恶唑-4-基甲氧基）-苄基] -1,3-二恶烷-r-2-羧酸13b在db / db小鼠和Zucker fa / fa大鼠中表现出有效的降血糖，降血脂和胰岛素增敏作用。
• [EN] NOVEL GPR 119 AGONISTS<br/>[FR] NOUVEAUX AGONISTES DE GPR 119
  申请人：CADILA HEALTHCARE LTD

  公开号：WO2010146605A1

  公开（公告）日：2010-12-23

  The present invention relates to novel GPR 119 agonists of the general Formula (I), their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, stereoisomers, and polymorphs. The invention also relates to processes for the preparation of the compounds of the invention, pharmaceutical compositions containing the compounds and to methods for treating one or both of diabetes and obesity using the compounds of the invention. The present invention is directed to G-protein coupled receptor (GPCR) agonists that are useful for the treatment of obesity, diabetes and related metabolic disorders.

  本发明涉及一般式（I）的新型GPR 119激动剂，其药学上可接受的盐，药学上可接受的溶剂化物，对映体，立体异构体和多形体。本发明还涉及制备本发明化合物的方法，含有该化合物的药物组合物以及使用本发明化合物治疗糖尿病和肥胖症的方法。本发明针对的是G蛋白偶联受体（GPCR）激动剂，可用于治疗肥胖症，糖尿病和相关代谢性疾病。
• NOVEL GPR 119 AGONISTS
  申请人：Pingali Harikishore

  公开号：US20120122905A1

  公开（公告）日：2012-05-17

  The present invention relates to novel GPR 119 agonists of the general Formula (I), their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, stereoisomers, and polymorphs. The invention also relates to processes for the preparation of the compounds of the invention, pharmaceutical compositions containing the compounds and to methods for treating one or both of diabetes and obesity using the compounds of the invention. The present invention is directed to G-protein coupled receptor (GPCR) agonists that are useful for the treatment of obesity, diabetes and related metabolic disorders.

  本发明涉及一般式（I）的新型GPR 119激动剂，其药学上可接受的盐、药学上可接受的溶剂化物、对映体、立体异构体和多晶形。本发明还涉及制备本发明化合物的过程、含有该化合物的制药组合物以及使用该化合物治疗糖尿病和肥胖症的方法。本发明针对的是G蛋白偶联受体（GPCR）激动剂，其可用于治疗肥胖症、糖尿病和相关代谢性疾病。
• Novel Antidiabetic Compounds
  申请人：Lohray Braj Bhushan

  公开号：US20090012069A1

  公开（公告）日：2009-01-08

  Disclosed are novel compounds of general formula (I) where the symbols are as defined in the specification, their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation. The compounds are useful in the treatment of diabetes and related diseases.

  本发明涉及一种新的化合物，其通式为（I），其中符号如规范中所定义，其互变异构体，立体异构体，药学上可接受的盐，包含它们的药物组合物，制备这些化合物的方法，这些化合物在医学中的应用以及其制备中所涉及的中间体。这些化合物在糖尿病和相关疾病的治疗中有用。